Differential expression and therapeutic efficacy of microRNA-346 in diabetic nephropathy mice

Experimental and Therapeutic Medicine

Volumn 10, Issue 1, 2015, Pages 106-112

  Zhang, Yong ^a,b   Xiao, Hou Qin ^b   Wang, Yang ^c   Yang, Zhuo Shun ^b   Dai, Long Jun ^b,d   Xu, Yan Cheng ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c QINGHAI UNIVERSITY   (China)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diabetes; Diabetic nephropathy; MicroRNA microarray; MicroRNA 346

Indexed keywords

MICRORNA; MICRORNA 141; MICRORNA 166; MICRORNA 17; MICRORNA 187; MICRORNA 192; MICRORNA 196A; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 21; MICRORNA 215; MICRORNA 216A; MICRORNA 29C; MICRORNA 346; MICRORNA 377; MICRORNA 451; MICRORNA 709; MICRORNA 98; PLASMID VECTOR; SMAD3 PROTEIN; SMAD4 PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; FIBROGENESIS; GLUCOSE HOMEOSTASIS; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; VALIDATION PROCESS; WESTERN BLOTTING;

EID: 84929628583     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2468     Document Type: Article

References (22)

1. Danaei G, Finucane MM, Lu Y, et al; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose): National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378: 31-40, 2011.
2. Gilbertson DT, Liu J, Xue JL, et al: Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 16: 3736-3741, 2005.
3. Hagiwara S, McClelland A and Kantharidis P: MicroRNA in diabetic nephropathy: Renin angiotensin, aGE/RAGE, and oxidative stress pathway. J Diabetes Res 2013: 173783, 2013.
4. Forbes JM and Cooper ME: Mechanisms of diabetic complications. Physiol Rev 93: 137-188, 2013.
5. Adler S: Diabetic nephropathy: Linking histology, cell biology, and genetics. Kidney Int 66: 2095-2106, 2004.
6. Susztak K, Raff AC, Schiffer M and Böttinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225-233, 2006.
7. Sharma K, McCue P and Dunn SR: Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284: F1138-F1144, 2003.
8. Yates LA, Norbury CJ and Gilbert RJ: The long and short of microRNA. Cell 153: 516-519, 2013.
9. Soifer HS, Rossi JJ and Saetrom P: MicroRNAs in disease and potential therapeutic applications. Mol Ther 15: 2070-2079, 2007.
10. Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-379, 2010.
11. Yang ZS, Tang XJ, Guo XR, et al: Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene (PTEN): An imaging demonstration. Onco Targets Ther 7: 441-446, 2014.
12. Krek A, Grün D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005.
13. Lorenzen JM, Haller H and Thum T: MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol 7: 286-294, 2011.
14. Krupa A, Jenkins R, Luo DD, et al: Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 21: 438-447, 2010.
15. Du B, Ma LM, Huang MB, Zhou H, Huang HL, Shao P, Chen YQ and Qu LH: High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett 584: 811-816, 2010.
16. Wang Q, Wang Y, Minto AW, et al: MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 22: 4126-4135, 2008.
17. Wang G, Kwan BC, Lai FM, et al: Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am J Hypertens 23: 78-84, 2010.
18. Tay Y, Rinn J and Pandolfi PP: The multilayered complexity of ceRNA crosstalk and competition. Nature 505: 344-352, 2014.
19. Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-865, 2013.
20. Meng XM, Huang XR, Chung AC, et al: Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol 21: 1477-1487, 2010.
21. Meng XM, Chung AC and Lan HY: Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond) 124: 243-254, 2013.
22. Kantharidis P, Wang B, Carew RM and Lan HY: Diabetes complications: The microRNA perspective. Diabetes 60: 1832-1837, 2011.